Teva wins battle with Pfizer over Viagra patent

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Teva wins battle with Pfizer over Viagra patent

viagra2-1-45.jpg

The Supreme Court of Canada on Thursday said that Pfizer’s blockbuster patent on the erectile dysfunction drug Viagra is invalid, reversing a Federal Court ruling that blocked Teva's application to market generic Viagra under the Patented Medicines (Notice of Compliance) Act (PM[NOC])

The decision is interesting in that the Supreme Court took the step of finding the patent invalid, rather than simply allowing the Canadian Minister of Health to grant the notice of compliance, said Sean Jackson of IP Osgoode.

viagra2-1-250.jpg

It has also clarified the Canadian disclosure requirement. “Sufficiency of disclosure lies at the very heart of the patent system, so adequate disclosure in the specification is a precondition for the granting of a patent,” said the judgment. In this respect, the Court found Pfizer’s patent lacking. The panel explained: “Although the patent includes the statement that ‘one of the especially preferred compounds induces penile erection in impotent males’, the patent application does not disclose that the compound that works is sildenafil, that it is found in Claim 7, or that the remaining compounds had not been found to be effective in treating ED.”

Pfizer’s patent was due to expire in 2014. Teva said its generic version of the drug will “result in millions in savings to consumers”.

more from across site and SHARED ros bottom lb

More from across our site

In-house counsel explain why firms should provide risk management advice that helps them achieve their goals
Attorneys at four firms explain the AI trends they expect in the future, including a potential shift in who plaintiffs sue for copyright infringement
The dispute at the Intellectual Property Enterprise Court pits Dryrobe against D-Robe and will include a ‘genericide’ element
Novo Nordisk losing patent rights covering Ozempic in Canada and a US Supreme Court decision favouring Ed Sheeran were also among the top talking points
The court will hand down its ruling in Iconix v Dream Pairs on Tuesday, June 24, in a case that concerns post-sale confusion
Developments included a stay in a row concerning the UPC’s jurisdiction and a timeline for the rollout of the long-awaited new CMS
Jorg Thomaier, who has been head of IP at the German pharma company since 2010, will leave later this year and hand the reins to the company’s head of patents
Companies must conduct thorough IP due diligence – even if it may not be mandatory
Celia Cheah at Wong & Partners in Malaysia says she is aiming to tap into the Baker McKenzie member firm’s international network and expand its IP portfolio
A team of partners that joined Boies Schiller Flexner say they would like to double the firm’s patent litigation capabilities
Gift this article